Malin Corporation

Positive Immunocore data point to 2021 commercialisation

  • Sectors : Pharma and healthcare
  • Companies : Malin Corporation

Ratings and price correct at time of issue.

  • Malin Corporation

    Closing Price: 400c

  • RATING 29/09/15

  • PREVIOUS RATING N/A

DAVY VIEW

Immunocore has announced positive phase III data for its uveal melanoma study, hitting the primary endpoint – which is the key marker reviewed by regulators. Based on this data, we think the therapy could be approved and commercially launched in 2021. From a Malin perspective, this important milestone for one of its key assets may increase the chances of a cash exit as the data could be supportive of an Immunocore IPO.

Download full report with analyst certification and important disclosures

Nov 23 2020, 11:45 GMT

Download